



(51) International Patent Classification:

A61K 38/00 (2006.01) C07K 14/605 (2006.01)

(21) International Application Number:

PCT/GB2021/051921

(22) International Filing Date:

27 July 2021 (27.07.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2011604.2 27 July 2020 (27.07.2020) GB

(71) Applicant: HEPTARES THERAPEUTICS LIMITED

[GB/GB]; Granta Park, Great Abington, Great Abington, Cambridge Cambridgeshire CB21 6DG (GB).

(72) Inventors: BROWN, Giles Albert; c/o HEPTARES

THERAPEUTICS LIMITED, Granta Park, Great Abington, Cambridge Cambridgeshire CB21 6DG (GB). CONGREVE, Miles Stuart; c/o HEPTARES THERAPEUTICS LIMITED, Granta Park, Great Abington, Cambridge Cambridgeshire CB21 6DG (GB). SCULLY, Conor; c/o HEPTARES THERAPEUTICS LIMITED, Granta Park, Great Abington, Cambridge Cambridgeshire CB21 6DG (GB).

(74) Agent: STRATAGEM IPM LIMITED; Meridian Court,

Comberton Road, Toft, Cambridge CB23 2RY (GB).


(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: GLP-1 RECEPTOR ANTAGONISTS



(1)

(57) Abstract: The disclosures herein relate to novel internally cyclic peptide compounds of formula (1) and salts thereof, wherein R^1 , AA^1 , AA^2 , LysR, X and Y are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with Glucagon-like peptide-1 (GLP-1) receptors.

GLP-1 Receptor Antagonists

This invention relates to a class of novel peptide compounds containing an internal lactam bridge, their salts, pharmaceutical compositions containing them and their use in therapy of the human body. In particular, the invention is directed to a class of compounds which are antagonists of Glucagon-like peptide (GLP) receptors. More particularly, the invention is directed to compounds that are antagonists of the Glucagon-like peptide-1 (GLP-1) receptor. The invention also relates to the manufacture and use of these compounds and compositions in the prevention or treatment of such diseases in which GLP receptors are involved.

Background of the Invention

The gastrointestinal hormone, glucagon-like peptide-1 (GLP-1) is released post-prandially (after a meal) from the L-cells of the gut and exerts a direct and potent glucose-dependent insulinotropic effect on the pancreatic b-cell.

GLP-1 is synthesised by posttranslational processing of proglucagon in the intestine. Cleavage of proglucagon by prohormone convertase 1/3 expressed only in the intestinal L-cells releases the incretin peptides GLP-1 and GLP-2. Secreted GLP-1 is rapidly degraded by the ubiquitous enzyme dipeptidyl peptides IV, resulting in an extremely short half-life for GLP-1 of ~2min.

GLP-1 acts via a specific receptor, glucagon-like peptide-1 receptor (GLP-1R), which belongs to the ClassB G protein-coupled receptor family. The GLP-1 receptor is widely distributed in pancreatic islets, brain, heart, kidney and the gastrointestinal tract. Binding of GLP-1 to its cognate receptor causes activation via the stimulatory G-protein Gas to activate adenylate cyclase resulting in the formation of intracellular cAMP levels, membrane depolarisation, elevation of intracellular calcium concentrations and enhanced exocytosis of insulin-containing granules located in the pancreatic b-cell. GLP-1 mediated sustained elevation of cAMP concentrations also stimulates pancreatic b-cell proliferation and enhances the differentiation of new beta cells from progenitor cells in the pancreatic duct epithelium.

GLP-1 also directly influences secretion of other hormones critical for control of plasma glucose. The pancreatic a-cell is under tonic inhibitory control of GLP-1 which strongly suppresses glucagon secretion through a paracrine action of somatostatin. Inhibition of glucagon via GLP-1 activity results in reduced hepatic production of glucose contributing to the overall GLP-1 effects on controlling postprandial glucose excursions.

In summary GLP-1 has been demonstrated to have profound antidiabetic effects through increased pancreatic glucose-stimulated insulin secretion resulting in increased glucose uptake in peripheral tissues. GLP-1 also plays key roles in inhibition of gastric emptying and antroduodenal motility, decrease satiety and food intake and weight loss.

5

The significant effects of GLP-1 described above have led to the hypothesis that clinical indications associated with exaggerated plasma concentrations of GLP-1, increased GLP-1 signalling and/or increased GLP-1R levels would result in hyperinsulinemia (excessive glucose-dependent insulin secretion) resulting on hypoglycaemia and evidence of

10 gastrointestinal dysfunction. Therefore conditions such as hyperinsulinemia and hypoglycaemia could be treated by blocking/antagonising activation of the GLP-1R.

15

The specific GLP-1 receptor antagonist exendin(9-39)amide [Ex(9-39)] was initially isolated from the venom of the lizard *Heloderma suspectum* and shares a degree of sequence

homology with GLP-1. Ex(9-39) is a selective, competitive peptide antagonist of the GLP-1 receptor that blocks GLP-1 mediated insulin secretion in vitro and in vivo and impairs glucose tolerance in response to endogenous and exogenous administration of GLP-1 in humans and rodent models. Ex(9-39) also inhibits insulin secretion in the absence of increased GLP-1 levels suggesting that Ex(9-39) is an inverse agonist of the GLP-1

20 receptor. These data suggest that the presence of the GLP-1 receptor alone is important for maintaining the glucose-competent status of pancreatic β -cells.

The influences of GLP-1 on islet β -cells are profound. GLP-1 promotes insulin release, the expression of proinsulin, insulin biosynthesis and mRNA stability. GLP-1 will also trigger

25 somatostatin secretion from islet δ -cells and suppress glucagon secretion from islet α -cells. Glucagons' effects oppose that of insulin raising the concentration of glucose in the bloodstream via effects directly on the liver increasing glycogenolysis and gluconeogenesis. This suggests that blocking the GLP-1 system will not only have direct effects on insulin secretion but will also release the suppression on glucagon secretion driving increased

30 glucose production by the liver.

Under healthy conditions the insulin-secreting actions of GLP-1 are normally highly glucose-dependent such that excessive GLP-1 secretion or sensitivity will not lead to hypoglycaemia. However clinical studies using administration of GLP-1 in the presence of a non glucose-

35 dependent insulin secretagogue (e.g. a sulphonylurea that acts on the KATP channel) or even directly infusing supraphysiological levels of GLP-1 into normal subjects is associated with an increased risk of hypoglycaemia.

Hypoglycemia not associated with diabetes is an uncommon clinical disorder. It is usually diagnosed when venous plasma glucose is $< 55\text{mg/ml}$ and supported by the presence of Whipple's triad. The subject of this application, a GLP-1R antagonists would have potential to treat a range of conditions associated with exaggerated plasma concentrations of GLP-1, increased GLP-1 signalling and/or increased GLP-1R levels resulting in hyperinsulinemia and/or hypoglycaemia and/or evidence of gastrointestinal dysfunction. These conditions would include both symptomatic treatment of hypoglycaemia, and, based on effects of GLP-1 on cell growth and differentiation, include the potential to influence the course of disease progression.

No new medicines have gained regulatory approval for the treatment of hyperinsulinemia hypoglycaemia (HH) in more than 20 years and there are significant short-comings associated with all current treatments. This has created a significant unmet medical need that spans from rare disease indications, to short-term requirements in approximately 10% of term admissions to neonatal units through to 0.2-1% of adults undergoing gastric bypass surgery. The validity of specifically targeting this mechanism has recently been clinically validated using the GLP-1 receptor antagonist peptide Ex9-39 in two distinct clinical populations.

Congenital hyperinsulinism (CHI) represents the most frequent cause of severe, persistent HH in newborn babies and children occurring in the UK in approximately 1/40,000 live births. The potential benefits of GLP-1R antagonists in CHI were demonstrated in rodent models of hyperinsulinism. These findings have been extended to testing Ex9-39 in human adult subjects with CHI owing to inactivating mutations in the KATP channel. The introduction of GLP-1 receptor antagonist treatment is predicted to relieve the pressure to perform irreversible pancreatectomy for many CHI patients. This will include patients with CHI in which there is growing evidence that GLP-1 hypersecretion is the underlying cause of inappropriate insulin release. GLP-1 antagonist treatment is predicted to have a sustained response profile, be effective in all patients and could be continued in adults without the need for dose titration or the adjustment for drug interactions resulting from the introduction of other pharmacological treatments.

Post bariatric surgery hypoglycaemia (PBHS). Gastric bypass surgery is being used increasingly in the treatment of morbidly obese type 2 diabetics and has been demonstrated to profoundly increase the levels of GLP-1 secretion. In a relatively small but clinically important number of patients this treatment can lead to a profound post-prandial hyperinsulinaemic hypoglycaemic state that can emerge after surgery with glucose

concentrations low enough (20-40 mg/dL) to cause seizures, altered mental status, loss of consciousness, cognitive dysfunction, disability, and death. There is no effective treatment for those patients exhibiting severe symptoms. The present invention provides a therapeutic intervention opportunity that can largely protect them should they suffer from post-bariatric hyperinsulinemia. Recently Salehi and colleagues have reported that this severe post-prandial hypoglycaemia in gastric bypass patients can be corrected by infusion of the GLP-1 antagonist Ex(9-39) consistent with a fundamental role for GLP-1 and its receptor in this mechanism.

The unmet medical need for the symptomatic treatment of hypoglycaemia extends beyond CHI and PBSH. Hyperinsulinism-induced hypoglycaemia encompasses a number of heterogeneous disorders principally characterised by the dysregulation of insulin secretion and resulting hypoglycaemia from pancreatic β -cells that may be effectively treated with a GLP1-R antagonist. These include but are not limited to indications of hypoglycaemia in children (e.g. neonatal hypoglycaemia, hypoglycaemia secondary to gastrostomy insertion, post prandial hypoglycaemia of uncertain aetiology) and adults (e.g. insulinomas, gastric bypass surgery-induced hypoglycaemia).

Transient unexplained hypoglycemia is one of the most common and important healthcare problems encountered in neonatology. In the UK, internal audits in our treatment centers suggest that approximately 10% of term baby admissions to neonatal units are solely due to hypoglycaemia with unknown causes. Given a live birth number of 800,000 in 2012, this suggests an incidence of ~8,000 new cases per year. A similar figure can also be derived from a USA-based study of neonatal hypoglycaemia in babies with extreme weights. A safe and effective treatment such as described in this invention would provide potential therapeutic benefit in this patient population.

Hyperinsulinemia and/or hypoglycaemia is observed in a subset of 'dumping syndrome' patients (e.g. as a complication of gastric bypass surgery and surgical procedures such as gastric/oesophageal surgery) that exhibit a very rapid gastric emptying and an exaggerated release of insulin and current hypotheses suggest a link between the rapid post-prandial glucose flux, GLP-1 secretion and hyperinsulinemia.

Tumour induced hypoglycaemia (TH) is a rare clinical condition that may occur as a result of eutopic insulin secretion by a pancreatic islet b-cell tumour (insulinoma) or ectopic tumour insulin secretion by a non-islet-cell tumour (examples include, but are not limited to, bronchial carcinoids and gastrointestinal stroma tumours). Insulinoma is a rare tumour with

an incidence of ~0.4/100,000 person-years and are usually small, sporadic intrapancreatic benign tumours.


Finally clinical data using the antagonist Ex(9-39) has consistently demonstrated the ability to block the consequences of raised GLP-1 levels and insulin levels. Other embodiments of this invention include the treatment of unexplained symptomatic hyperinsulinemia and/or associated hypoglycaemia in a range of conditions such as hypoglycemia due to hyperinsulinism associated with leucine sensitivity, hypoglycemia due to hyperinsulinism associated with non-malignant insulinomas, inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy, hyperinsulinmia and hypoglycaemia in polycystic ovary syndrome, sulphonylurea-induced toxicity in T2DM, Prader-Willi syndrome, Adrenal Insufficiency and Addison's Disease, Beckwith-Wiedemann syndrome, Soto's Syndrome, Costello Syndrome, Timothy Syndrome, Kabuki Syndrome, Congenital Disorders of Glycosylation, Late dumping syndrome, Reactive hypoglycaemia infants of diabetic mothers, Trisomy 13, Central hypoventilation syndrome, Leprechaunism (insulin resistance syndrome), Mosaic Turner Syndrome, Usher Syndrome, Non-insulinoma pancreatogenous hypoglycaemia, Factitious hypoglycaemia, Insulin gene receptor mutations, Insulin autoimmune syndrome, Non-islet cells tumor hypoglycemia (NICTH) and withdrawal from alcoholic and other addictive substances.

Summary of the Invention

The present invention relates to novel compounds with antagonist activity at the GLP-1 receptor, pharmaceutical compositions comprising these, and use of the compounds for the manufacture of medicaments for treatment of diseases.

Accordingly, in one embodiment the invention provides a compound of the formula (1):

A compound comprising a sequence of formula (1):



wherein;

R^1 is H, NHR^2 or CH_2R^2 ; where R^2 is selected from: H, C_{1-6} alkyl, $(\text{CH}_2)_n\text{aryl}$ and $(\text{CH}_2)_n\text{heteroaryl}$; where n is 1 to 6;

AA¹ is -Leu- or -Nle-;

AA² is -NHCR^{3a}R^{3b}CO-; wherein R^{3a} is hydrogen or a C₁₋₃ alkyl group, or is joined to R^{3b} to form a 3-6 membered ring optionally containing one or more heteroatoms selected from N and O; and R^{3b} is C₁₋₆ alkyl, (CH₂)_naryl, (CH₂)_nOH or (CH₂)_nOR⁴, or is joined to R^{3a} to form a 3-6 membered ring optionally containing one or more heteroatoms selected from N and O; where R⁴ is C₁₋₆ alkyl and n is 1 to 6;

LysR is an optionally N-substituted substituted Lysine residue;

X is a sequence -Gln-AA³-Glu-AA⁴-Glu-AA⁵-Val-AA⁶-Leu-Phe-AA⁷-AA⁸-Trp-Leu-Lys-AA⁹-AA¹⁰;

wherein AA³ is -Met- or -Nle-; where when AA³ is -Met-, LysR is an N-substituted lysine residue;

AA⁴ is -Glu- or -Gln-;

AA⁵ is -Ser- or -Ala-;

AA⁶ is -Arg- or -DArg-;

AA⁷ is a group -NHCHR⁵CO-; where R⁵ is a C₁₋₆ alkyl group;

AA⁸ is -Glu- joined to AA⁹ via a lactam bridge;

AA⁹ is -Lys- joined to AA⁸ via a lactam bridge;

AA¹⁰ is -Gly-, -Ser-, -DAla- or -βAla-;

Y is absent or is a sequence -AA¹¹-AA¹²-AA¹³-AA¹⁴-AA¹⁵-AA¹⁶-AA¹⁷-AA¹⁸-AA¹⁹-AA²⁰-AA²¹-

wherein AA¹¹ is -Gly- or -Ser-;

AA¹² is -Pro- or -Ser-;

AA¹³ is -Ser-, -DSer- or -Lys-;

AA¹⁴ is -Ser-, -DSer-, -Lys- or -Phe-;

AA¹⁵ is absent or is -Ser-, -DSer-, -Gly-, -Glu- or -Lys-;

AA¹⁶ is absent or is -Ser-, -DSer-, -Ala-, -Lys- or -Tyr-;

AA¹⁷ is absent or is -Ser-, -DSer-, -Pro-, -Glu- or -Lys-;

AA¹⁸ is absent or is -Ser-, -DSer-, -Pro-, -Lys- or -LysR-;

AA¹⁹ is absent or is -Pro- or -Glu-;


AA²⁰ is absent or is -Ser- or -Tyr-;

AA²¹ is absent or is -Glu-;

wherein the X or Y C-terminus is a carboxyl group or a carboxamide group, or is adjoined to any natural or non-natural amino acid sequence or any other moiety, functional group or groups;


- 5 or a tautomeric or stereochemically isomeric form thereof or a prodrug, salt or zwitterion thereof.

Particular compounds also include compounds of formula (1a):




- 10 or a tautomeric or stereochemically isomeric form thereof or a prodrug, salt or zwitterion thereof, wherein AA¹, AA², LysR, X and Y are as defined above.

Particular compounds also include compounds of formula (1b):




- 15 or a tautomeric or stereochemically isomeric form thereof or a prodrug, salt or zwitterion thereof, wherein AA¹, AA², LysR, X and Y are as defined above.

Particular compounds also include compounds of formula (1c):



- 20 or a tautomeric or stereochemically isomeric form thereof or a prodrug, salt or zwitterion thereof, wherein AA¹, AA², LysR, X and Y are as defined above.

Particular compounds also include compounds of formula (1d):



(1d)

or a tautomeric or stereochemically isomeric form thereof or a prodrug, salt or zwitterion thereof, wherein AA¹, AA², LysR, X and Y are as defined above.

- 5 The compounds herein may be used as antagonists of the Glucagon-like peptide-1 (GLP-1) receptor. The compounds may be used in the manufacture of medicaments. The compounds or medicaments may be for use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with GLP-1 receptors including unexplained symptomatic hyperinsulinemia and/or associated hypoglycaemia in a range of conditions such as
- 10 hypoglycemia due to hyperinsulinism associated with leucine sensitivity, hypoglycemia due to hyperinsulinism associated with non-malignant insulinomas, inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy, hyperinsulinmia and hypoglycaemia in polycystic ovary syndrome, sulphonylurea-induced toxicity in T2DM, Prader-Willi syndrome, Adrenal Insufficiency and Addison's Disease, Beckwith-Wiedemann syndrome, Soto's
- 15 Syndrome, Costello Syndrome, Timothy Syndrome, Kabuki Syndrome, Congenital Disorders of Glycosylation, Late dumping syndrome, Reactive hypoglycaemia infants of diabetic mothers, Trisomy 13, Central hypoventilation syndrome, Leprechaunism (insulin resistance syndrome), Mosaic Turner Syndrome, Usher Syndrome, Non-insulinoma pancreatogenous hypoglycaemia, Factitious hypoglycaemia, Insulin gene receptor mutations, Insulin
- 20 autoimmune syndrome, Non-islet cells tumor hypoglycemia (NICTH) and withdrawal from alcoholic and other addictive substances.

Detailed Description of the Invention


- This invention relates to novel compounds. The invention also relates to the use of novel
- 25 compounds as antagonists of GLP-1 receptors. The invention further relates to the use of novel compounds in the manufacture of medicaments for use as GLP-1 receptor antagonists or for the treatment of disorders associated with GLP-1 receptors. The invention further relates to compounds, compositions and medicaments which are selective antagonists of the GLP-1 receptor with respect to other GLP receptor sub-types.

30

The invention further relates to compounds, compositions and medicaments useful for the treatment of unexplained symptomatic hyperinsulinemia conditions and/or associated

hypoglycaemia conditions such as hypoglycemia due to hyperinsulinism associated with leucine sensitivity, hypoglycemia due to hyperinsulinism associated with non-malignant insulinomas, inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy, hyperinsulinmia and hypoglycaemia in polycystic ovary syndrome, sulphonylurea-induced toxicity in T2DM, Prader-Willi syndrome, Adrenal Insufficiency and Addison's Disease, Beckwith-Wiedemann syndrome, Soto's Syndrome, Costello Syndrome, Timothy Syndrome, Kabuki Syndrome, Congenital Disorders of Glycosylation, Late dumping syndrome, Reactive hypoglycaemia infants of diabetic mothers, Trisomy 13, Central hypoventilation syndrome, Leprechaunism (insulin resistance syndrome), Mosaic Turner Syndrome, Usher Syndrome, Non-insulinoma pancreatogenous hypoglycaemia, Factitious hypoglycaemia, Insulin gene receptor mutations, Insulin autoimmune syndrome, Non-islet cells tumor hypoglycemia (NICTH) and withdrawal from alcoholic and other addictive substances.

Accordingly, in one embodiment the invention provides a compound comprising a sequence of formula (1):



wherein;

R^1 is H, NHR^2 or CH_2R^2 ; where R^2 is selected from: H, C_{1-6} alkyl, $(\text{CH}_2)_n\text{aryl}$ and $(\text{CH}_2)_n\text{heteroaryl}$; where n is 1 to 6;

AA^1 is -Leu- or -Nle-;

AA^2 is $-\text{NHCR}^{3a}\text{R}^{3b}\text{CO}-$; wherein R^{3a} is hydrogen or a C_{1-3} alkyl group, or is joined to R^{3b} to form a 3-6 membered ring optionally containing one or more heteroatoms selected from N and O; and R^{3b} is C_{1-6} alkyl, $(\text{CH}_2)_n\text{aryl}$, $(\text{CH}_2)_n\text{OH}$ or $(\text{CH}_2)_n\text{OR}^4$, or is joined to R^{3a} to form a 3-6 membered ring optionally containing one or more heteroatoms selected from N and O; where R^4 is C_{1-6} alkyl and n is 1 to 6;

LysR is an optionally N-substituted substituted Lysine residue;

X is a sequence -Gln- AA^3 -Glu- AA^4 -Glu- AA^5 -Val- AA^6 -Leu-Phe- AA^7 - AA^8 -Trp-Leu-Lys- AA^9 - AA^{10} -;

wherein AA³ is -Met- or -Nle-; where when AA³ is -Met-, LysR is an N-substituted lysine residue;

AA⁴ is -Glu- or -Gln-;

5 AA⁵ is -Ser- or -Ala-;

AA⁶ is -Arg- or -DArg-;

AA⁷ is a group -NHCHR⁵CO-; where R⁵ is a C₁₋₆ alkyl group;

AA⁸ is -Glu- joined to AA⁹ via a lactam bridge;

AA⁹ is -Lys- joined to AA⁸ via a lactam bridge;

10 AA¹⁰ is -Gly-, -Ser-, -DAla- or -βAla-;

Y is absent or is a sequence -AA¹¹-AA¹²-AA¹³-AA¹⁴-AA¹⁵-AA¹⁶-AA¹⁷-AA¹⁸-AA¹⁹-AA²⁰-AA²¹-

wherein AA¹¹ is -Gly- or -Ser-;

15 AA¹² is -Pro- or -Ser-;

AA¹³ is -Ser-, -DSer- or -Lys-;

AA¹⁴ is -Ser-, -DSer-, -Lys- or -Phe-;

AA¹⁵ is absent or is -Ser-, -DSer-, -Gly-, -Glu- or -Lys-;

AA¹⁶ is absent or is -Ser-, -DSer-, -Ala-, -Lys- or -Tyr-;

20 AA¹⁷ is absent or is -Ser-, -DSer-, -Pro-, -Glu- or -Lys-;

AA¹⁸ is absent or is -Ser-, -DSer-, -Pro-, -Lys- or -LysR-;

AA¹⁹ is absent or is -Pro- or -Glu-;

AA²⁰ is absent or is -Ser- or -Tyr-;

AA²¹ is absent or is -Glu-;

25

wherein the X or Y C-terminus is a carboxyl group or a carboxamide group, or is adjoined to any natural or non-natural amino acid sequence or any other moiety, functional group or groups;

30 or a tautomeric or stereochemically isomeric form thereof or a prodrug, salt or zwitterion thereof.

R¹ can be H, NH₂, NHBn or CH₂Bn. R¹ can be H. R¹ can be hydrogen. R¹ can be NH₂. R¹ can be NHBn. R¹ can be CH₂Bn. R¹ can be NH-benzyl. R¹ can be CH₂-benzyl.

35

R² can be H. R² can be hydrogen. R² can be Bn. R² can be benzyl.

AA¹ can be -Leu-. AA¹ can be -Nle-.


AA² can be -NHCR^{3a}R^{3b}CO-; wherein R^{3a} is hydrogen or methyl, and R^{3b} is selected from methyl, ethyl, isobutyl, *n*-butyl, CH₂OH, CH₂CH₂OH, CH₂OCH₃, CH₂-cyclopropyl, Bn, CH₂Bn or CH₂CH₂Bn.

R^{3a} can be hydrogen or methyl. R^{3a} can be hydrogen. R^{3a} can be methyl.


R^{3b} can be selected from methyl, ethyl, isobutyl, *n*-butyl, CH₂OH, CH₂CH₂OH, CH₂OCH₃, CH₂-cyclopropyl, Bn, CH₂Bn or CH₂CH₂Bn.

R^{3a} and R^{3b} can be joined to form a ring. R^{3a} and R^{3b} can be joined to form a cyclobutyl or an oxetanyl ring.

AA² can be selected from:



AA² can be selected from:



5

LysR can be an unsubstituted lysine residue.


LysR can be an N-substituted Lysine residue, wherein the N-substituent is selected from: -CO(CH₂)_qCH₃; -CO(CH₂)_qCO₂H; -CO(CH₂)_qCHCH₂; -COO(CH₂)_qCH₃; -COO(CH₂)_qCO₂H and -COO(CH₂)_qCHCH₂; where q is 1 to 22.

- 10 LysR can be an N-substituted Lysine residue, wherein the N-substituent is -COO(CH₂)_qCHCH₂; where q is 1 to 22.











LysR can be an N-substituted Lysine residue, wherein the N-substituent is -COO(CH₂)_qCHCH₂; where q is 1.

- 15 LysR can be an N-substituted Lysine residue, wherein the N-substituent is -COOCH₂CHCH₂.


Lys R can be



- 20 LysR can be an N-substituted Lysine residue, wherein the N-substituent is a group -L-G; wherein L is selected from the group consisting of:



and G is selected from the group consisting of:



where m is 1 to 23;

5 p is 1 to 3;

r is 1 to 20;


s is 0 to 3;

t is 0 to 4;


and w is 0 to 4

10

LysR can be



LysR can be



15 AA³ can be -Met-. AA³ can be -Nle-. When AA³ is -Met-, LysR is an N-substituted lysine residue.

AA⁴ can be -Glu-. AA⁴ can be -Gln-.

AA⁵ can be -Ser-. AA⁵ can be -Ala-.

AA⁶ can be -Arg-. AA⁶ can be -DArg-.

20 AA⁷ can be a group -NHCHR⁵CO-; where R⁵ is selected from isopropyl, sec-butyl and neopentyl. R⁵ can be isopropyl. R⁵ can be sec-butyl. R⁵ can be neopentyl.

AA⁷ can be -Ile-. AA⁷ can be -Val-. AA⁷ can be a *tert*-butyl alanine residue.

AA¹⁰ can be -Gly-. AA¹⁰ can be -Ser-. AA¹⁰ can be -DAla-. AA¹⁰ can be -βAla-.

25 AA⁸ and AA⁹ can be joined via a lactam bridge.

Y can be absent or present. Y can be absent. Y can be present.

AA¹¹ can be -Gly-. AA¹¹ can be -Ser-.

AA¹² can be -Pro-. AA¹² can be -Ser-.

AA¹³ can be -Ser-. AA¹³ can be -DSer-. AA¹³ can be -Lys-.

5 AA¹⁴ can be -Ser-. AA¹⁴ can be -DSer-. AA¹⁴ can be -Lys-. AA¹⁴ can be -Phe-.

AA¹⁵ can be absent. AA¹⁵ can be -Ser-. AA¹⁵ can be -DSer-. AA¹⁵ can be -Gly-. AA¹⁵ can be -Glu-. AA¹⁵ can be -Lys-.

AA¹⁶ can be absent. AA¹⁶ can be -Ser-. AA¹⁶ can be -DSer-. AA¹⁶ can be -Ala-. AA¹⁶ can be -Lys-. AA¹⁶ can be -Tyr-.

10 AA¹⁷ can be absent. AA¹⁷ can be -Ser-. AA¹⁷ can be -DSer-. AA¹⁷ can be -Pro-. AA¹⁷ can be -Glu-. AA¹⁷ can be -Lys-.

AA¹⁸ can be absent. AA¹⁸ can be -Ser-. AA¹⁸ can be -DSer-. AA¹⁸ can be -Pro-. AA¹⁸ can be -Lys-. AA¹⁸ can be -LysR-.

AA¹⁹ can be absent. AA¹⁹ can be -Pro-. AA¹⁹ can be -Glu-.

15 AA²⁰ can be absent. AA²⁰ can be -Ser-. AA²⁰ can be -Tyr-.

AA²¹ can be absent. AA²¹ can be -Glu-.

When Y is absent, the X C-terminus can be a carboxamide group. When Y is absent, the X C-terminus can be a carboxyl group. When Y is absent, the X C-terminus can be adjoined to any natural or non-natural amino acid sequence or any other moiety, functional group or groups.


The Y C-terminus can be a carboxamide group. The Y C-terminus can be a carboxyl group. the Y C-terminus can be adjoined to any natural or non-natural amino acid sequence or any other moiety, functional group or groups.

25 The compound can be a compound wherein R¹ is NHBn, AA¹ is -Leu-, AA² is -D-HomoPhe-, LysR is -Lys-, AA³ is -Nle-, AA⁴ is -Glu-, AA⁵ is -Ala-, AA⁶ is -DArg-, AA⁷ is -Ile- and AA¹⁰ is -Gly-, where the X C-terminus is a carboxamide group.

30 The compound can be a compound wherein R¹ is NHBn, AA¹ is -Nle-, AA² is -Aib-, LysR is -Lys-, AA³ is -Nle-, AA⁴ is -Glu-, AA⁵ is -Ala-, AA⁶ is -DArg-, AA⁷ is -Ile- and AA¹⁰ is -Gly-, where the X C-terminus is a carboxamide group.

35 The compound can be a compound wherein R¹ is NHBn, AA¹ is -Leu-, AA² is -D-Ala-, LysR is -Lys-, AA³ is -Nle-, AA⁴ is -Glu-, AA⁵ is -Ala-, AA⁶ is -DArg-, AA⁷ is -Ile-, AA¹⁰ is -Gly-, AA¹¹ is -Gly-, AA¹² is -Pro-, AA¹³ is -Ser-, AA¹⁴ is -Ser-, AA¹⁵ is -Ser-, AA¹⁶ is -Ser-, AA¹⁷ is -Ser- and AA¹⁸ is -Ser-, where the Y C-terminus is a carboxamide group.


The compound can be a compound of formula (1a):



or a tautomeric or stereochemically isomeric form thereof or a prodrug, salt or zwitterion thereof, wherein AA¹, AA², LysR, X and Y are as defined above.

5


The compound can be a compound of formula (1b):



or a tautomeric or stereochemically isomeric form thereof or a prodrug, salt or zwitterion thereof, wherein AA¹, AA², LysR, X and Y are as defined above.

10


The compound can be a compound of formula (1c):



or a tautomeric or stereochemically isomeric form thereof or a prodrug, salt or zwitterion thereof, wherein AA¹, AA², LysR, X and Y are as defined above.

15

The compound can be a compound of formula (1d):




or a tautomeric or stereochemically isomeric form thereof or a prodrug, salt or zwitterion thereof, wherein AA¹, AA², LysR, X and Y are as defined above.

20


The compound can be a compound selected from the group consisting of:

Example 15:




Example 30:

17



Example 32:



or a tautomeric or stereochemically isomeric form thereof or a prodrug, salt or zwitterion thereof.

The compound can be selected from any one of Examples 1 to 33 shown in Table 1:

Table1

		AA1	AA2	LYSR		AA3		AA4		AA5		AA6			AA7	AA8				AA9	AA10	AA11	AA12	AA13	AA14	AA15	AA16	AA17	AA18
Example 1	ASP	LEU	D-PHE	LYS	GLN	NLE	GLU	GLU	GLU	ALA	VAL	ARG	LEU	PHE	ILE	CycloGLU	TRP	LEU	LYS	CycloLYS	GLY	NH2							
Example 2	Bn-ASP	LEU	D-HomoPHE	LYS	GLN	NLE	GLU	GLU	GLU	ALA	VAL	ARG	LEU	PHE	ILE	CycloGLU	TRP	LEU	LYS	CycloLYS	D-ALA	NH2							
Example 3	Bn-ASP	LEU	D-HomoPHE	LYS-yGlu-2xOEG C18 diacid	GLN	NLE	GLU	GLU	GLU	ALA	VAL	D-ARG	LEU	PHE	ILE	CycloGLU	TRP	LEU	LYS	CycloLYS	D-ALA	NH2							
Example 4	succinate	LEU	D-HomoPHE	LYS	GLN	NLE	GLU	GLU	GLU	ALA	VAL	ARG	LEU	PHE	ILE	CycloGLU	TRP	LEU	LYS	CycloLYS	D-ALA	NH2							
Example 5	succinate	LEU	D-HomoPHE	LYS-yGlu-2xOEG C18 diacid	GLN	NLE	GLU	GLU	GLU	ALA	VAL	ARG	LEU	PHE	ILE	CycloGLU	TRP	LEU	LYS	CycloLYS	GLY	NH2							
Example 6	succinate	LEU	D-HomoPHE	LYS-yGlu-2xOEG C18 diacid	GLN	NLE	GLU	GLU	GLU	ALA	VAL	D-ARG	LEU	PHE	ILE	CycloGLU	TRP	LEU	LYS	CycloLYS	D-ALA	NH2							
Example 7	Bn-ASP	LEU	D-HomoPHE	LYS	GLN	NLE	GLU	GLU	GLU	ALA	VAL	D-ARG	LEU	PHE	tBuALA	CycloGLU	TRP	LEU	LYS	CycloLYS	D-ALA	NH2							
Example 8	Bn-ASP	LEU	D-HomoPHE	LYS-yGlu-2xOEG C18 diacid	GLN	NLE	GLU	GLU	GLU	ALA	VAL	D-ARG	LEU	PHE	tBuALA	CycloGLU	TRP	LEU	LYS	CycloLYS	D-ALA	NH2							
Example 9	Bn-ASP	LEU	SER	LYS	GLN	NLE	GLU	GLU	GLU	ALA	VAL	D-ARG	LEU	PHE	tBuALA	CycloGLU	TRP	LEU	LYS	CycloLYS	D-ALA	NH2							
Example 10	Bn-ASP	LEU	D-HomoPHE	LYS	GLN	NLE	GLU	GLU	GLU	ALA	VAL	D-ARG	LEU	PHE	ILE	CycloGLU	TRP	LEU	LYS	CycloLYS	D-ALA	NH2							
Example 11	Bn-ASP	NLE	D-HomoPHE	LYS	GLN	NLE	GLU	GLU	GLU	ALA	VAL	D-ARG	LEU	PHE	ILE	CycloGLU	TRP	LEU	LYS	CycloLYS	D-ALA	NH2							
Example 12	Bn-ASP	LEU	D-SER	LYS	GLN	NLE	GLU	GLU	GLU	ALA	VAL	D-ARG	LEU	PHE	ILE	CycloGLU	TRP	LEU	LYS	CycloLYS	D-ALA	NH2							
Example 13	Bn-ASP	LEU	SER	LYS	GLN	NLE	GLU	GLU	GLU	ALA	VAL	D-ARG	LEU	PHE	ILE	CycloGLU	TRP	LEU	LYS	CycloLYS	D-ALA	NH2							
Example 14	Bn-ASP	LEU	D-HomoPHE	LYS	GLN	NLE	GLU	GLU	GLU	ALA	VAL	ARG	LEU	PHE	ILE	CycloGLU	TRP	LEU	LYS	CycloLYS	GLY	NH2							
Example 15	Bn-ASP	LEU	D-HomoPHE	LYS	GLN	NLE	GLU	GLU	GLU	ALA	VAL	D-ARG	LEU	PHE	ILE	CycloGLU	TRP	LEU	LYS	CycloLYS	GLY	NH2							
Example 16	Bn-ASP	LEU	D-HomoPHE	LYS-yGlu-2xOEG C18 diacid	GLN	NLE	GLU	GLU	GLU	ALA	VAL	ARG	LEU	PHE	ILE	CycloGLU	TRP	LEU	LYS	CycloLYS	GLY	NH2							
Example 17	succinate	LEU	D-HomoPHE	LYS	GLN	NLE	GLU	GLU	GLU	ALA	VAL	ARG	LEU	PHE	ILE	CycloGLU	TRP	LEU	LYS	CycloLYS	GLY	NH2							
Example 18	succinate	LEU	D-HomoPHE	LYS	GLN	NLE	GLU	GLU	GLU	ALA	VAL	D-ARG	LEU	PHE	ILE	CycloGLU	TRP	LEU	LYS	CycloLYS	GLY	NH2							
Example 19	Bn-ASP	LEU	D-HomoPHE	LYS	GLN	NLE	GLU	GLU	GLU	ALA	VAL	ARG	LEU	PHE	tBuALA	CycloGLU	TRP	LEU	LYS	CycloLYS	GLY	NH2							
Example 20	Bn-ASP	LEU	D-HomoPHE	LYS	GLN	NLE	GLU	GLU	GLU	ALA	VAL	D-ARG	LEU	PHE	tBuALA	CycloGLU	TRP	LEU	LYS	CycloLYS	GLY	NH2							
Example 21	Bn-ASP	LEU	D-HomoPHE	LYS-yGlu-2xOEG C18 diacid	GLN	NLE	GLU	GLU	GLU	ALA	VAL	ARG	LEU	PHE	tBuALA	CycloGLU	TRP	LEU	LYS	CycloLYS	GLY	NH2							
Example 22	Bn-ASP	LEU	D-HomoPHE	LYS-yGlu-2xOEG C18 diacid	GLN	NLE	GLU	GLU	GLU	ALA	VAL	D-ARG	LEU	PHE	tBuALA	CycloGLU	TRP	LEU	LYS	CycloLYS	GLY	NH2							
Example 23	Bn-ASP	LEU	SER	LYS	GLN	NLE	GLU	GLU	GLU	ALA	VAL	ARG	LEU	PHE	ILE	CycloGLU	TRP	LEU	LYS	CycloLYS	GLY	NH2							
Example 24	Bn-ASP	LEU	D-HomoPHE	LYS-yGlu-2xOEG C18 diacid	GLN	NLE	GLU	GLU	GLU	ALA	VAL	D-ARG	LEU	PHE	ILE	CycloGLU	TRP	LEU	LYS	CycloLYS	D-ALA	NH2							

Example 25	Bn-ASP	LEU	D-ALA	LYS	GLN	NLE	GLU	GLU	GLU	ALA	VAL	D-ARG	LEU	PHE	ILE	CycloGLU	TRP	LEU	LYS	CyclolYS	GLY	NH2									
Example 26	Bn-ASP	NLE	D-ALA	LYS	GLN	NLE	GLU	GLU	GLU	ALA	VAL	D-ARG	LEU	PHE	ILE	CycloGLU	TRP	LEU	LYS	CyclolYS	GLY	NH2									
Example 27	Bn-ASP	NLE	D-ABU	LYS	GLN	NLE	GLU	GLU	GLU	ALA	VAL	D-ARG	LEU	PHE	ILE	CycloGLU	TRP	LEU	LYS	CyclolYS	GLY	NH2									
Example 28	Succinate	LEU	D-ALA	LYS	GLN	NLE	GLU	GLU	GLU	ALA	VAL	ARG	LEU	PHE	VAL	CycloGLU	TRP	LEU	LYS	CyclolYS	GLY	NH2									
Example 29	Bn-ASP	LEU	D-ALA	LYS	GLN	NLE	GLU	GLU	GLU	ALA	VAL	ARG	LEU	PHE	VAL	CycloGLU	TRP	LEU	LYS	CyclolYS	GLY	NH2									
Example 30	Bn-ASP	NLE	AIB	LYS	GLN	NLE	GLU	GLU	GLU	ALA	VAL	D-ARG	LEU	PHE	ILE	CycloGLU	TRP	LEU	LYS	CyclolYS	GLY	NH2									
Example 31	Bn-ASP	LEU	AIB	LYS	GLN	NLE	GLU	GLU	GLU	ALA	VAL	D-ARG	LEU	PHE	ILE	CycloGLU	TRP	LEU	LYS	CyclolYS	GLY	NH2									
Example 32	Bn-ASP	LEU	D-ALA	LYS	GLN	NLE	GLU	GLU	GLU	ALA	VAL	D-ARG	LEU	PHE	ILE	CycloGLU	TRP	LEU	LYS	CyclolYS	GLY	GLY	PRO	SER	SER	SER	SER	SER	SER	NH2	
Example 33	Succinate	LEU	D-ALA	LYS	GLN	NLE	GLU	GLU	GLU	ALA	VAL	ARG	LEU	PHE	VAL	CycloGLU	TRP	LEU	LYS	CyclolYS	GLY	GLY	PRO	SER	SER	SER	SER	SER	SER	NH2	

Standard amino acid symbols are used in Table 1 where appropriate. In cases where a standard symbol is not available, the following representations are used:

Succinate	Bn-ASP	D-HomoPHE	tBuALA	

The sequence -CycloGlu-Trp-Leu-Lys-CycloLys- represents:

Specific examples of compounds include compounds having GLP-1 receptor antagonist activity.

The compounds of the invention may be used in a pharmaceutical composition comprising a compound of the invention and a pharmaceutically acceptable excipient.

The compounds of the invention may be used in medicine.

The compounds of the invention may be used in the treatment of disorders associated with GLP-1 receptors.

The compounds of the invention may be used in the treatment of unexplained symptomatic hyperinsulinemia conditions and/or associated hypoglycaemia conditions such as hypoglycemia due to hyperinsulinism associated with leucine sensitivity, hypoglycemia due to hyperinsulinism associated with non-malignant insulinomas, inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy, hyperinsulinemia and hypoglycaemia in polycystic ovary syndrome, sulphonylurea-induced toxicity in T2DM, Prader-Willi syndrome, Adrenal Insufficiency and Addison's Disease, Beckwith-Wiedemann syndrome, Soto's Syndrome, Costello Syndrome, Timothy Syndrome, Kabuki Syndrome, Congenital Disorders of Glycosylation, Late dumping syndrome, Reactive hypoglycaemia infants of diabetic mothers, Trisomy 13, Central hypoventilation syndrome, Leprechaunism (insulin resistance syndrome), Mosaic Turner Syndrome, Usher Syndrome, Non-insulinoma pancreatogenous hypoglycaemia, Factitious hypoglycaemia, Insulin gene receptor mutations, Insulin autoimmune syndrome, Non-islet cells tumor hypoglycemia (NICTH) and withdrawal from alcoholic and other addictive substances,

Definitions

In this application, the following definitions apply, unless indicated otherwise.

The term “alkyl”, “aryl”, and “heteroaryl” are used in their conventional sense (e.g. as defined in the IUPAC Gold Book) unless indicated otherwise.

The term “treatment”, in relation to the uses of any of the compounds described herein, including those of the formula (1), is used to describe any form of intervention where a compound is administered to a subject suffering from, or at risk of suffering from, or potentially at risk of suffering from the disease or disorder in question. Thus, the term “treatment” covers

both preventative (prophylactic) treatment and treatment where measurable or detectable symptoms of the disease or disorder are being displayed.

The term “effective therapeutic amount” as used herein (for example in relation to methods of treatment of a disorder, disease or condition) refers to an amount of the compound which is effective to produce a desired therapeutic effect. For example, if the condition is pain, then the effective therapeutic amount is an amount sufficient to provide a desired level of pain relief. The desired level of pain relief may be, for example, complete removal of the pain or a reduction in the severity of the pain.

To the extent that any of the compounds described have chiral centres, the present invention extends to all optical isomers of such compounds, whether in the form of racemates or resolved enantiomers. The invention described herein relates to all crystal forms, solvates and hydrates of any of the disclosed compounds however so prepared. To the extent that any of the compounds disclosed herein have acid or basic centres such as carboxylates or amino groups, then all salt forms of said compounds are included herein. In the case of pharmaceutical uses, the salt should be seen as being a pharmaceutically acceptable salt.

Salts or pharmaceutically acceptable salts that may be mentioned include acid addition salts and base addition salts. Such salts may be formed by conventional means, for example by reaction of a free acid or a free base form of a compound with one or more equivalents of an appropriate acid or base, optionally in a solvent, or in a medium in which the salt is insoluble, followed by removal of said solvent, or said medium, using standard techniques (e.g. in vacuo, by freeze-drying or by filtration). Salts may also be prepared by exchanging a counter-ion of a compound in the form of a salt with another counter-ion, for example using a suitable ion exchange resin.

Examples of pharmaceutically acceptable salts include acid addition salts derived from mineral acids and organic acids, and salts derived from metals such as sodium, magnesium, potassium and calcium.

Examples of acid addition salts include acid addition salts formed with acetic, 2,2-dichloroacetic, adipic, alginic, aryl sulfonic acids (e.g. benzenesulfonic, naphthalene-2-sulfonic, naphthalene-1,5-disulfonic and p-toluenesulfonic), ascorbic (e.g. L-ascorbic), L-aspartic, benzoic, 4-acetamidobenzoic, butanoic, (+) camphoric, camphor-sulfonic, (+)-(1S)-camphor-10-sulfonic,

capric, caproic, caprylic, cinnamic, citric, cyclamic, dodecylsulfuric, ethane-1,2-disulfonic, ethanesulfonic, 2-hydroxyethanesulfonic, formic, fumaric, galactaric, gentisic, glucoheptonic, gluconic (e.g. D-gluconic), glucuronic (e.g. D-glucuronic), glutamic (e.g. L-glutamic), α -oxoglutaric, glycolic, hippuric, hydrobromic, hydrochloric, hydriodic, isethionic, lactic (e.g. (+)-L-lactic and ($\pm$)-DL-lactic), lactobionic, maleic, malic (e.g. (-)-L-malic), malonic, ($\pm$)-DL-mandelic, metaphosphoric, methanesulfonic, 1-hydroxy-2-naphthoic, nicotinic, nitric, oleic, orotic, oxalic, palmitic, pamoic, phosphoric, propionic, L-pyroglutamic, salicylic, 4-amino-salicylic, sebacic, stearic, succinic, sulfuric, tannic, tartaric (e.g. (+)-L-tartaric), thiocyanic, undecylenic and valeric acids.

Also encompassed are any solvates of the compounds and their salts. Preferred solvates are solvates formed by the incorporation into the solid state structure (e.g. crystal structure) of the compounds of the invention of molecules of a non-toxic pharmaceutically acceptable solvent (referred to below as the solvating solvent). Examples of such solvents include water, alcohols (such as ethanol, isopropanol and butanol) and dimethylsulfoxide. Solvates can be prepared by recrystallising the compounds of the invention with a solvent or mixture of solvents containing the solvating solvent. Whether or not a solvate has been formed in any given instance can be determined by subjecting crystals of the compound to analysis using well known and standard techniques such as thermogravimetric analysis (TGA), differential scanning calorimetry (DSC) and X-ray crystallography.

The solvates can be stoichiometric or non-stoichiometric solvates. Particular solvates may be hydrates, and examples of hydrates include hemihydrates, monohydrates and dihydrates. For a more detailed discussion of solvates and the methods used to make and characterise them, see Bryn *et al*, Solid-State Chemistry of Drugs, Second Edition, published by SSCI, Inc of West Lafayette, IN, USA, 1999, ISBN 0-967-06710-3.

The term "pharmaceutical composition" in the context of this invention means a composition comprising an active agent and comprising additionally one or more pharmaceutically acceptable carriers. The composition may further contain ingredients selected from, for example, diluents, adjuvants, excipients, vehicles, preserving agents, fillers, disintegrating agents, wetting agents, emulsifying agents, suspending agents, sweetening agents, flavouring agents, perfuming agents, antibacterial agents, antifungal agents, lubricating agents and dispersing agents, depending on the nature of the mode of administration and dosage forms.

The compositions may take the form, for example, of tablets, dragees, powders, elixirs, syrups,

liquid preparations including suspensions, sprays, inhalants, tablets, lozenges, emulsions, solutions, cachets, granules, capsules and suppositories, as well as liquid preparations for injections, including liposome preparations.

5 The compounds of the invention may contain one or more isotopic substitutions, and a reference to a particular element includes within its scope all isotopes of the element. For example, a reference to hydrogen includes within its scope ^1H , ^2H (D), and ^3H (T). Similarly, references to carbon and oxygen include within their scope respectively ^{12}C , ^{13}C and ^{14}C and ^{16}O and ^{18}O . In an analogous manner, a reference to a particular functional group also includes
10 within its scope isotopic variations, unless the context indicates otherwise. For example, a reference to an alkyl group such as an ethyl group or an alkoxy group such as a methoxy group also covers variations in which one or more of the hydrogen atoms in the group is in the form of a deuterium or tritium isotope, e.g. as in an ethyl group in which all five hydrogen atoms are in the deuterium isotopic form (a perdeuteroethyl group) or a methoxy group in which all three
15 hydrogen atoms are in the deuterium isotopic form (a trideuteromethoxy group). The isotopes may be radioactive or non-radioactive.

Therapeutic dosages may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed. Determination of the
20 proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with the smaller dosages which are less than the optimum dose of the compound. Thereafter the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired.

25 The magnitude of an effective dose of a compound will, of course, vary with the nature of the severity of the condition to be treated and with the particular compound and its route of administration. The selection of appropriate dosages is within the ability of one of ordinary skill in this art, without undue burden. In general, the daily dose range may be from about 10 μg to
30 about 30 mg per kg body weight of a human and non-human animal, preferably from about 50 μg to about 30 mg per kg of body weight of a human and non-human animal, for example from about 50 μg to about 10 mg per kg of body weight of a human and non-human animal, for example from about 100 μg to about 30 mg per kg of body weight of a human and non-human animal, for example from about 100 μg to about 10 mg per kg of body weight of a human and

non-human animal and most preferably from about 100 µg to about 1 mg per kg of body weight of a human and non-human animal.

Pharmaceutical Formulations

5 While it is possible for the active compound to be administered alone, it is preferable to present it as a pharmaceutical composition (e.g. formulation).

Accordingly, in another embodiment of the invention, there is provided a pharmaceutical composition comprising at least one compound of the formula (1) as defined above together with at least one pharmaceutically acceptable excipient.

10

The composition may be a composition suitable for injection. The injection may be intra-venous (IV) or subcutaneous. The composition may be supplied in a sterile buffer solution or as a solid which can be suspended or dissolved in sterile buffer for injection.

15 The pharmaceutically acceptable excipient(s) can be selected from, for example, carriers (e.g. a solid, liquid or semi-solid carrier), adjuvants, diluents (e.g. solid diluents such as fillers or bulking agents; and liquid diluents such as solvents and co-solvents), granulating agents, binders, flow aids, coating agents, release-controlling agents (e.g. release retarding or delaying polymers or waxes), binding agents, disintegrants, buffering agents, lubricants, preservatives, anti-fungal
20 and antibacterial agents, antioxidants, buffering agents, tonicity-adjusting agents, thickening agents, flavouring agents, sweeteners, pigments, plasticizers, taste masking agents, stabilisers or any other excipients conventionally used in pharmaceutical compositions.

The term “pharmaceutically acceptable” as used herein means compounds, materials,
25 compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of a subject (e.g. a human subject) without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. Each excipient must also be “acceptable” in the sense of being compatible with the other ingredients of the formulation.

30

Pharmaceutical compositions containing compounds of the formula (1) can be formulated in accordance with known techniques, see for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA, USA.

Suitable formulations typically contain 0-20% (w/w) buffers, 0-50% (w/w) cosolvents, and/or 0-99% (w/w) Water for Injection (WFI) (depending on dose and if freeze dried). Formulations for intramuscular depots may also contain 0-99% (w/w) oils.

5 The compounds of the formula (1) will generally be presented in unit dosage form and, as such, will typically contain sufficient compound to provide a desired level of biological activity. For example, a formulation may contain from 1 nanogram to 2 grams of active ingredient, e.g. from 1 nanogram to 2 milligrams of active ingredient. Within these ranges, particular sub-ranges of compound are 0.1 milligrams to 2 grams of active ingredient (more usually from 10 milligrams to 10 1 gram, e.g. 50 milligrams to 500 milligrams), or 1 microgram to 20 milligrams (for example 1 microgram to 10 milligrams, e.g. 0.1 milligrams to 2 milligrams of active ingredient).

The active compound will be administered to a patient in need thereof (for example a human or animal patient) in an amount sufficient to achieve the desired therapeutic effect (effective 15 amount). The precise amounts of compound administered may be determined by a supervising physician in accordance with standard procedures.

EXAMPLES

The invention will now be illustrated, but not limited, by reference to the specific embodiments 20 described in the following examples.

EXAMPLES 1 TO 33

The compounds of Examples 1 to 33 shown in Table 1 above have been prepared. Their LCMS properties and the methods used to prepare them are set out in Table 2. The starting materials for each of the Examples are commercial unless indicated otherwise. 25

General procedures

Where no preparative routes are included, the relevant intermediate is commercially available. Commercial reagents were utilized without further purification. Room temperature (rt) refers to approximately 20-27°C. 30

Analytical Methods

LCMS analysis of compounds was performed under electrospray conditions.

Analytical Method A

35 MS ion determined using LCMS method below under electrospray conditions, HPLC retention time (R_T) determined using HPLC method below, purity > 95% by HPLC unless indicated.

LCMS: Agilent 1200 HPLC&6410B Triple Quad, Column: Xbridge C18 3.5um 2.1*30mm. Gradient [time (min)/solvent B(%):0.0/10,0.9/80,1.5/90,8.5/5,1.51/10. (Solvent A=1mL of TFA in 1000 mL Water; Solvent B=1mL of TFA in 1000 mL of MeCN); Injection volume 5 µL (may vary); UV detection 220 nm 254 nm 210 nm; Column temperature 25°C; 1.0 mL/min.

- 5 HPLC: Agilent Technologies 1200, Column: Gemini-NX C18 5um 110A 150*4.6mm. Gradient [time (min)/solvent B(%):0.0/30,20/60,20.1/90,23/90. (Solvent A=1mL of TFA in 1000 mL Water; Solvent B=1mL of TFA in 1000 mL of MeCN); Injection volume 5 µL (may vary); UV detection 220 nm 254 nm; Column temperature 25°C; 1.0 mL/min.

10 Analytical Method B

Instrument: Thermo Scientific Orbitrap Fusion; Column: Phenomenex Kinetex Biphenyl 100 Å, 2.6 µm, 2.1 x 50 mm; Gradient [time (min)/solvent B in A (%): 0.00/10, 0.30/10, 0.40/60, 1.10/90, 1.70/90, 1.75/10, 1.99/10, 2.00/10; Solvents: Solvent A = 0.1% formic acid in water; Solvent B = 0.1% formic acid in acetonitrile; Injection volume 5 µL; Column temperature 25 °C; 15 Flow rate 0.8 mL/min.

Synthesis of Intermediates and Compounds

The following examples are provided to illustrate preferred aspects of the invention and are not intended to limit the scope of the invention. All Fmoc-amino acids are commercially available

20

Synthesis of Examples 1-33

Standard Fmoc solid phase peptide synthesis (SPPS) was used to synthesize the linear peptides which were then cleaved from the resin and purified.

25 **General method for Peptide Synthesis:**

Method a – Exemplified by the Synthesis of Example 25

Peptide Synthesis

- 1) Add DCM to the vessel containing Rink Amide MBHA Resin (sub: 0.35 mmol/g, 0.3 mmol, 0.86 g) and swell for 2 hours.
- 30 2) Drain and then wash with DMF (5 times, drain between each wash).
- 3) A solution of 20% piperidine in DMF was added agitate with N₂ bubbling for 30 min.
- 4) Drain and wash with DMF (5 times, drain between each wash).
- 5) Add Fmoc-amino acid solution (3.0 equivalents in DMF) and mix for 30 seconds, then add activation buffer (HBTU (2.85 equivalents) and DIEA (6 equivalents) in DMF), agitate with N₂
- 35 bubbling for 1 hour.
- 6) The coupling reaction was monitored by ninhydrin test

- 7) If required repeat steps 4 to 6 for same amino acid coupling if inefficient coupling occurs
 8) Repeat steps 2 to 6 for next amino acid coupling.

Note: for the acids in the table below different protecting groups and / or coupling agents were used.

Step	Materials	Coupling reagents
14	Fmoc-Glu(OtBu)-OH (3.0 eq)	HOBt (3 eq) and DIC (3.0 eq)
21	(S)-2-(benzylamino)-4-(tert-butoxy)-4-oxobutanoic acid (2.0 eq)	HATU (1.9 eq) and DIEA (4.0 eq)

5

Peptide sidechain deprotection cyclisation:

- 1) Add DCM to the resin and agitate with N₂ bubbling, then add PhSiH₃ (10 eq), Pd(PPh₃)₄ (0.2 eq) agitate with N₂ for 15 mins for 3 times.
- 2) The resin was washed with DCM three times and then DMF three times.
- 10 3) The resin was washed with 0.5% Sodium diethyldithiocarbamate trihydrate DMF and 0.5% DIEA in DMF for ten times.
- 4) HATU (2 eq) and DIEA (4 eq) were added to the resin in DMF and agitate with N₂ bubbling for 1 hour.
- 5) The resin was washed with MeOH three times and dried *in vacuo*.

15

Peptide Cleavage and Purification:

- 1) Add cleavage buffer (92.5%TFA/2.5%EDT/2.5%TIS/2.5%H₂O) to the flask containing the side chain protected peptide on resin at room temperature and stir for 3 hours.
- 2) Filter and collect the peptide solution.
- 20 3) The peptide is precipitated with cold tert-butyl methyl ether and centrifuged (3 min at 3000 rpm).
- 4) Residue washed with tert-butyl methyl ether (2 times).
- 5) Crude peptide dried under vacuum for 2 hours.
- 6) The crude peptide was purified by prep-HPLC. Prep-HPLC Conditions: Instrument: Gilson
- 25 281. Solvent: A- 0.1% TFA in H₂O, B- acetonitrile, Column: Luna C18 (200×25 mm; 10 μm) and Gemini C18 (150×30 mm; 5 μm) in series. Gradient [time (min)/solvent B (%]):0.0/15, 60.0/55, 60.1/90, 70/90, 70.1/10, at 20 mL/min with UV detection (wave length = 215/254 nm) and then lyophilized to give Example 25 (32.1 mg, 4.06% yield).

30

Table 2 - HRMS and LCMS properties of purify peptides represented by Examples 1-33

Example	HRMS (Method B)	LCMS / HPLC (Method A)
1	HRMS (HESI/FT) m/z: [M+3H] ³⁺ Calcd for C122H193N30O31 2571.4214; Found 858.1508	m/z 858.3 [M+3H] ³⁺ , R _T = 11.85 min
2	HRMS (HESI/FT) m/z: [M+3H] ³⁺ Calcd for C131H203N30O31 2689.4995; Found 897.5102	m/z 897.9 [M+3H] ³⁺ , R _T = 13.07 min
3	HRMS (HESI/FT) m/z: [M+3H] ³⁺ Calcd for C166H264N33O43 3404.925; Found 1135.9872	m/z 1136.5 [M+3H] ³⁺ , R _T = 12.46 min
4	HRMS (HESI/FT) m/z: [M+3H] ³⁺ Calcd for C124H196N29O31 2584.4417; Found 862.4912	m/z 862.9 [M+3H] ³⁺ , R _T = 11.02 min
5	HRMS (HESI/FT) m/z: [M+3H] ³⁺ Calcd for C158H255N32O43 3285.8516; Found 1096.2946	m/z 1096.6 [M+3H] ³⁺ , R _T = 14.42 min
6	HRMS (HESI/FT) m/z: [M+3H] ³⁺ Calcd for C159H257N32O43 3299.8672; Found 1100.9668	m/z 1101.4 [M+3H] ³⁺ , R _T = 11.63 min
7	ND	m/z 902.5 [M+3H] ³⁺ , R _T = 13.24 min
8	HRMS (HESI/FT) m/z: [M+3H] ³⁺ Calcd for C167H267N34O42 3417.9568; Found 1140.6591	m/z 1141.1 [M+3H] ³⁺ , R _T = 12.97 min
9	HRMS (HESI/FT) m/z: [M+3H] ³⁺ Calcd for C125H199N30O32 2629.4631; Found 877.4979	m/z 877.7 [M+3H] ³⁺ , R _T = 10.98 min
10	HRMS (HESI/FT) m/z: [M+3H] ³⁺ Calcd for C131H203N30O31 2689.4995; Found 897.5094	m/z 897.8 [M+3H] ³⁺ , R _T = 9.46 min
11	HRMS (HESI/FT) m/z: [M+3H] ³⁺ Calcd for C131H203N30O31 2689.4995; Found 897.5103	m/z 897.9 [M+3H] ³⁺ , R _T = 9.46 min
12	HRMS (HESI/FT) m/z: [M+3H] ³⁺ Calcd for C124H197N30O32 2615.4475; Found 872.8264	m/z 873.1 [M+3H] ³⁺ , R _T = 11.91 min
13	HRMS (HESI/FT) m/z: [M+3H] ³⁺ Calcd for C124H197N30O32 2615.4475; Found 872.8257	m/z 873.1 [M+3H] ³⁺ , R _T = 11.96 min
14	HRMS (HESI/FT) m/z: [M+3H] ³⁺ Calcd for C130H201N30O31 2675.4839; Found 892.8422	m/z 893.1 [M+3H] ³⁺ , R _T = 12.85 min
15	HRMS (HESI/FT) m/z: [M+3H] ³⁺ Calcd for C130H201N30O31 2675.4839; Found 892.8375	m/z 893.0 [M+3H] ³⁺ , R _T = 12.22 min
16	HRMS (HESI/FT) m/z: [M+3H] ³⁺ Calcd for C165H262N33O43 3390.9094; Found 1131.3114	m/z 1131.7 [M+3H] ³⁺ , R _T = 12.40 min
17	HRMS (HESI/FT) m/z: [M+3H] ³⁺ Calcd for C123H194N29O31 2570.426; Found 857.8198	m/z 858.1 [M+3H] ³⁺ , R _T = 14.21 min
18	HRMS (HESI/FT) m/z: [M+3H] ³⁺ Calcd for C123H194N29O31 2570.426; Found 857.8234	m/z 858.2 [M+3H] ³⁺ , R _T = 13.82 min
19	HRMS (HESI/FT) m/z: [M+3H] ³⁺ Calcd for C131H200N30O31 2689.4995; Found 897.5144	m/z 897.8 [M+3H] ³⁺ , R _T = 13.32 min
20	HRMS (HESI/FT) m/z: [M+3H] ³⁺ Calcd for C131H203N30O31 2689.4995; Found 897.5105	m/z 897.9 [M+3H] ³⁺ , R _T = 13.56 min
21	HRMS (HESI/FT) m/z: [M+3H] ³⁺ Calcd for C131H203N30O31 2689.4995; Found 897.5105	m/z 1136.4 [M+3H] ³⁺ , R _T = 12.82 min
22	HRMS (HESI/FT) m/z: [M+3H] ³⁺ Calcd for C166H264N33O43 3404.925; Found 1135.9867	m/z 1136.3 [M+3H] ³⁺ , R _T = 12.84 min
23	HRMS (HESI/FT) m/z: [M+3H] ³⁺ Calcd for C166H264N33O43 3404.925; Found 1135.9857	m/z 868.5 [M+3H] ³⁺ , R _T = 12.27 min
24	HRMS (HESI/FT) m/z: [M+3H] ³⁺ Calcd for C166H264N33O43 3404.925; Found 1135.9879	m/z 1136.4 [M+3H] ³⁺ , R _T = 12.57 min
25	HRMS (HESI/FT) m/z: [M+3H] ³⁺ Calcd for C123H195N30O31 2585.437; Found 862.8253	m/z 862.8 [M+3H] ³⁺ , R _T = 11.95 min

26	HRMS (HESI/FT) m/z: [M+3H] ³⁺ Calcd for C123H195N30O31 2585.437; Found 862.8233	m/z 862.9 [M+3H] ³⁺ , R _T = 11.96 min
27	HRMS (HESI/FT) m/z: [M+3H] ³⁺ Calcd for C124H197N30O31 2599.4526; Found 867.4960	m/z 867.6 [M+3H] ³⁺ , R _T = 12.53 min
28	HRMS (HESI/FT) m/z: [M+3H] ³⁺ Calcd for C115H186N29O31 2466.3635; Found 823.1318	m/z 823.1 [M+3H] ³⁺ , R _T = 13.67 min
29	HRMS (HESI/FT) m/z: [M+3H] ³⁺ Calcd for C122H193N30O31 2571.4214; Found 858.1510	m/z 858.1 [M+3H] ³⁺ , R _T = 12.28 min
30	HRMS (HESI/FT) m/z: [M+3H] ³⁺ Calcd for C124H197N30O31 2599.4526; Found 867.4953	m/z 867.5 [M+3H] ³⁺ , R _T = 10.68 min
31	HRMS (HESI/FT) m/z: [M+3H] ³⁺ Calcd for C124H197N30O31 2599.4526; Found 867.4959	m/z 867.6 [M+3H] ³⁺ , R _T = 10.56 min
32	HRMS (HESI/FT) m/z: [M+3H] ³⁺ Calcd for C148H235N38O45 3261.7034; Found 1088.2462	m/z 1088.3 [M+3H] ³⁺ , R _T = 13.00 min
33	HRMS (HESI/FT) m/z: [M+3H] ³⁺ Calcd for C140H226N37O45 3142.6299; Found 1048.5573	m/z 1048.5 [M+3H] ³⁺ , R _T = 11.17 min

ND – Not determined

Biological Activity

- 5 The following examples are provided to illustrate preferred aspects of the invention and are not intended to limit the scope of the invention.

Example A. In vitro pharmacological characterization of GLP-1 peptides - Functional antagonism of human GLP1 receptors, cAMP accumulation assay

- 10 Antagonist inhibition of cAMP production upon stimulation of GLP-1R with agonist ligand (GLP-1(7-36) amide peptide, Tocris) was assessed using HiRange cAMP kit (Cisbio). The method followed a two-step protocol provided in the kit. In brief, HEK cells infected with 1% v/v GLP-1R Bacmam for 24h were harvested using cell dissociation solution (Gibco), centrifuged and resuspended in the assay buffer (HBSS (Lonza) supplemented with 0.5 mM IBMX (Tocris)).
- 15 DMSO stock of test compounds were serially diluted in the assay buffer and added to 96-well half area white plates (Costar). Final DMSO concentration in the assay was 0.3%. 20K cells per well were added to plates followed by 30 min incubation (humidified air (5% CO₂), 37°C). Then, cells were stimulated for further 30 min (humidified air (5% CO₂), 37°C) by addition of an equivalent to EC₈₀ concentration of GLP-1(7-36) peptide. Intracellular accumulation of cAMP
- 20 was stopped by addition of the HTRF detection reagents in lysis buffer, provided in the kit. Following 1-hour incubation at RT, plates were read on Pherastar FS (BMG Labtech, Inc.) Dotmatics Studies software was used for fitting data to a four-parameter concentration response curve. Calculated IC₅₀ values were corrected for the agonist concentration using an adaptation of the Cheng-Prusoff equation to generate functional pK_b values: $fpK_b = -\log_{10}\left(\frac{IC_{50}}{[A]}\right)$.

Example	Human GLP-1R antagonist cAMP	Example	Human GLP-1R antagonist cAMP
	fpKb		fpKb
Ex 9-39	7.8	17	8.5
1	8.2	18	8.5
2	8.1	19	8.3
3	8.0	20	8.2
4	8.3	21	8.1
5	8.1	22	8.1
6	8.0	23	8.2
7	8.0	24	8.2
8	8.0	25	8.3
9	8.0	26	8.3
10	8.3	27	8.4
11	8.1	28	7.9
12	8.0	29	8.2
13	8.1	30	8.7
14	8.5	31	8.3
15	8.6	32	8.5
16	8.3	33	8.0

Example B. In vitro pharmacological characterization of GLP-1 peptides – Functional antagonism of mouse GLP1 receptors, cAMP accumulation assay:

- 5 Antagonist inhibition of cAMP production upon stimulation of GLP-1R with agonist ligand was assessed using HitHunter cAMP assay (DiscoverX). The method followed antagonist procedure steps provided in the kit. In brief, CHO-K1 cells stably expressing mouse GLP-1R were thawed and plated at 10K cells per well in CP05 reagent in the total volume of 20 μ l into white walled, 384-well plates and incubated overnight at 37°C
- 10 in Cytomat. On the day of the assay, the media was replaced with 15 μ l of HBSS/10mM HEPES. DMSO stock of test compounds were serially diluted in DMSO and then further diluted in the HBSS/10mM HEPES, 5 μ l of each concentration were added to the plate followed by 30 min incubation at 37°C. Final DMSO concentration in the assay was 1%. Cells were stimulated for further 30 min at 37°C by addition of an equivalent to EC₈₀
- 15 concentration of Exendin-4. Intracellular accumulation of cAMP was stopped by addition of the HitHunter detection reagents in lysis buffer, provided in the kit. Following 1-hour incubation at RT in the dark, plates were read on Envision (Perkin Elmer). Dotmatics Studies software was used for fitting data to a four-parameter concentration response curve. Calculated IC₅₀ values were corrected for the agonist concentration using an

adaptation of the Cheng-Prusoff equation to generate functional pK_b values:

$$fpK_b = -\log_{10}\left(\frac{IC_{50}}{\frac{[A]}{[EC_{50}] + 1}}\right).$$

Example	Mouse GLP-1R antagonist cAMP
	fpK_b
Ex 9-39	7.2
12	7.4
13	7.6
15	7.6
16	7.6
23	7.1
25	6.9
26	7.0
27	6.8
30	7.4
31	7.3
32	8.3

Example C: IPGTT challenge in normal mice

- 5 The aim of this study is to evaluate the effects of intravenous administration of a lead GLP1 antagonist peptide on blocking/reducing/antagonising exendin-4-induced (GLP-1 receptor agonist) improvements in glucose tolerance in lean male C57BL/6J mice. Glucose was administered by the intraperitoneal route.

10 MATERIALS AND METHODS

Lean, male C57BL/6J JAX mice were singly housed upon arrival and throughout the study in polypropylene cages on a normal phase 12 h light-dark cycle (lights on 07:00). Relative humidity will typically be 55±15% with prolonged periods below 40%RH or above 70%RH avoided. Animals had free access to standard maintenance diet and tap water *ad libitum* for the duration of the study unless otherwise stated.

EXEPRIMENTAL PROCEDURE

- Animals were habituated to the animal unit and diet for approximately 2 weeks with daily handling for the 5 days prior to the study in order to familiarise the animals to the dosing protocol. Animals were randomised on the basis of body weight and ensured that groups were balanced as closely as possible for mean body weight.

The day prior to the ipGTT, all animals were fasted (free access to water maintained) to ensure. The day of the experiment the animals were moved to a separate room. A baseline blood sample was taken from all animals prior to Treatment 1 (20 minutes pre-glucose). Five minutes later, mice were dosed with Treatment 1 by the intravenous route (15 minutes pre-glucose).


5 Treatment 2 (Exendin-4 or vehicle) was administered 10 minutes prior to the glucose load (all groups). Ten minutes after dosing with Treatment 2 animals were administered a glucose load of D-glucose by the intraperitoneal route (2.0 g/kg at a volume of 5 ml/kg at a concentration of 400 mg/ml). Blood samples were taken 3 minutes before glucose administration and 10, 30, 60, 90 and 120 minutes post glucose administration. Plasma samples were subsequently assayed
10 for glucose and insulin at the 10 minute time as single replicates and data analysed by robust regression and AUC 0 to 120 minutes calculated for the glucose data (as total AUC and AUC from baseline) by trapezoidal rule and analysed by the same methodology.

Figure 1 shows the results for Example 12. Glucose AUC over the 0-120min time period post-glucose administration. Example compound effects compared to Exendin-4 by Williams' test.
15 *p<0.05, **p<0.01, ***p<0.001.

Figure 2 shows the results for Example 12. Plasma insulin (ng/ml) at 10 minutes post-glucose administration. Example compound effects compared to Exendin-4 by Williams' test. *p<0.05,
20 **p<0.01, ***p<0.001.

Claims

1. A compound comprising a sequence of formula (1):



5 wherein;

R^1 is H, NHR^2 or CH_2R^2 ; where R^2 is selected from: H, C_{1-6} alkyl, $(\text{CH}_2)_n\text{aryl}$ and $(\text{CH}_2)_n\text{heteroaryl}$; where n is 1 to 6;

10 AA^1 is -Leu- or -Nle-;

AA^2 is $-\text{NHCR}^{3a}\text{R}^{3b}\text{CO}-$; wherein R^{3a} is hydrogen or a C_{1-3} alkyl group, or is joined to R^{3b} to form a 3-6 membered ring optionally containing one or more heteroatoms selected from N and O; and R^{3b} is C_{1-6} alkyl, $(\text{CH}_2)_n\text{aryl}$, $(\text{CH}_2)_n\text{OH}$ or $(\text{CH}_2)_n\text{OR}^4$, or is joined to R^{3a} to form a 3-6 membered ring optionally containing one or more heteroatoms selected from N and O; where R^4 is C_{1-6} alkyl and n is 1 to 6;

LysR is an optionally N-substituted substituted Lysine residue;

20 X is a sequence $-\text{Gln}-\text{AA}^3-\text{Glu}-\text{AA}^4-\text{Glu}-\text{AA}^5-\text{Val}-\text{AA}^6-\text{Leu}-\text{Phe}-\text{AA}^7-\text{AA}^8-\text{Trp}-\text{Leu}-\text{Lys}-\text{AA}^9-\text{AA}^{10}-$;

wherein AA^3 is -Met- or -Nle-; where when AA^3 is -Met-, LysR is an N-substituted lysine residue;

25 AA^4 is -Glu- or -Gln-;

AA^5 is -Ser- or -Ala-;

AA^6 is -Arg- or -DArg-;

AA^7 is a group $-\text{NHCHR}^5\text{CO}-$; where R^5 is a C_{1-6} alkyl group;

AA^8 is -Glu- joined to AA^9 via a lactam bridge;

30 AA^9 is -Lys- joined to AA^8 via a lactam bridge;

AA^{10} is -Gly-, -Ser-, -DAla- or $-\beta\text{Ala}-$;

Y is absent or is a sequence -AA¹¹-AA¹²-AA¹³-AA¹⁴-AA¹⁵-AA¹⁶-AA¹⁷-AA¹⁸-AA¹⁹-AA²⁰-AA²¹-

wherein AA¹¹ is -Gly- or -Ser-;

AA¹² is -Pro- or -Ser-;

AA¹³ is -Ser-, -DSer- or -Lys-;

AA¹⁴ is -Ser-, -DSer-, -Lys- or -Phe-;

AA¹⁵ is absent or is -Ser-, -DSer-, -Gly-, -Glu- or -Lys-;

AA¹⁶ is absent or is -Ser-, -DSer-, -Ala-, -Lys- or -Tyr-;

AA¹⁷ is absent or is -Ser-, -DSer-, -Pro-, -Glu- or -Lys-;

AA¹⁸ is absent or is -Ser-, -DSer-, -Pro-, -Lys- or -LysR-;

AA¹⁹ is absent or is -Pro- or -Glu-;

AA²⁰ is absent or is -Ser- or -Tyr-;

AA²¹ is absent or is -Glu-;


wherein the X or Y C-terminus is a carboxyl group or a carboxamide group, or is adjoined to any natural or non-natural amino acid sequence or any other moiety, functional group or groups;

or a tautomeric or stereochemically isomeric form thereof or a prodrug, salt or zwitterion thereof.

2. The compound according to claim 1, wherein R¹ is selected from H, NH₂, NHBn and CH₂Bn.


3. The compound according to claim 2, wherein R¹ is NHBn.

4. The compound according to claim 1 which is a compound of formula (1a):



or a tautomeric or stereochemically isomeric form thereof or a prodrug, salt or zwitterion thereof, wherein AA¹, AA², LysR, X and Y are as defined in claim 1.


5. The compound according to claim 1 which is a compound of formula (1b):



or a tautomeric or stereochemically isomeric form thereof or a prodrug, salt or zwitterion thereof, wherein AA¹, AA², LysR, X and Y are as defined in claim 1.

5

6. The compound according to claim 1 which is a compound of formula (1c):




or a tautomeric or stereochemically isomeric form thereof or a prodrug, salt or zwitterion thereof, wherein AA¹, AA², LysR, X and Y are as defined in claim 1.

10

7. The compound according to any one of claims 1 to 6, wherein AA¹ is -Leu-.
8. The compound according to any one of claims 1 to 7, wherein R^{3a} is hydrogen or methyl and R^{3b} is selected from methyl, ethyl, isobutyl, *n*-butyl, CH₂OH, CH₂CH₂OH, CH₂OCH₃, CH₂-cyclopropyl, Bn, CH₂Bn or CH₂CH₂Bn.
9. The compound according to any one of claims 1 to 7, wherein R^{3a} and R^{3b} form a cyclobutyl or an oxetanyl ring.


15

10. The compound according to any one of claims 1 to 7, wherein AA² is selected from:




5

11. The compound according to claim 10, wherein AA² is selected from



10

12. The compound according to claim 11, wherein AA² is:





13. The compound according to any one of claims 1 to 12, wherein the group LysR is an unsubstituted lysine residue.

14. The compound according to any one of claims 1 to 12, wherein LysR is an N-substituted Lysine residue, wherein the N-substituent is selected from: $-\text{CO}(\text{CH}_2)_q\text{CH}_3$; $-\text{CO}(\text{CH}_2)_q\text{CO}_2\text{H}$; $-\text{CO}(\text{CH}_2)_q\text{CHCH}_2$; $-\text{COO}(\text{CH}_2)_q\text{CH}_3$; $-\text{COO}(\text{CH}_2)_q\text{CO}_2\text{H}$ and $-\text{COO}(\text{CH}_2)_q\text{CHCH}_2$; where q is 1 to 22.


15. The compound according to any one of claims 1 to 12, wherein LysR is an N-substituted Lysine residue, wherein the N-substituent is a group -L-G;

wherein L is selected from the group consisting of:





and G is selected from the group consisting of:



where m is 1 to 23;

p is 1 to 3;


r is 1 to 20;

s is 0 to 3;

t is 0 to 4;


and w is 0 to 4.

16. The compound according to claim 14, wherein the group LysR is:



5

17. The compound according to claim 14, wherein the group LysR is selected from:



10 18. The compound according to any one of claims 1 to 17, wherein AA⁸ and AA⁹ are joined via a lactam bridge.


19. The compound according to any one of claims 1 to 18, wherein the X or Y C-terminus is a carboxamide group.

15

20. The compound according to claim 1 which is selected from any one of Examples 1 to 33.


21. The compound according to claim 1 which is selected from:

Example 15:




5

Example 30:



Example 32:



10 22. The compound according to any one of claims 1 to 21 having GLP-1 receptor antagonist activity.

23. A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 22 and a pharmaceutically acceptable excipient.

15

24. The compound or composition according to any one of claims 1 to 23 for use in the treatment of unexplained symptomatic hyperinsulinemia conditions and/or associated hypoglycaemia conditions.

20 25. The compound according to claim 24, wherein the condition is selected from unexplained symptomatic hyperinsulinemia and/or associated hypoglycaemia in a range of conditions such as hypoglycemia due to hyperinsulinism associated with leucine sensitivity, hypoglycemia due to hyperinsulinism associated with non-malignant insulinomas, inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy,
25 hyperinsulinemia and hypoglycaemia in polycystic ovary syndrome, sulphonylurea-

induced toxicity in T2DM, Prader-Willi syndrome, Adrenal Insufficiency and Addison's Disease, Beckwith-Wiedemann syndrome, Soto's Syndrome, Costello Syndrome, Timothy Syndrome, Kabuki Syndrome, Congenital Disorders of Glycosylation, Late dumping syndrome, Reactive hypoglycaemia infants of diabetic mothers, Trisomy 13, Central hypoventilation syndrome, Leprechaunism (insulin resistance syndrome), Mosaic Turner Syndrome, Usher Syndrome, Non-insulinoma pancreatogenous hypoglycaemia, Factitious hypoglycaemia, Insulin gene receptor mutations, Insulin autoimmune syndrome, Non-islet cells tumor hypoglycemia (NICTH) and withdrawal from alcoholic and other addictive substances.

5

10

Figure 1





Figure 2



INTERNATIONAL SEARCH REPORT

International application No
PCT/GB2021/051921

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K38/00 C07K14/605
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, BIOSIS, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 2020/074927 A2 (HEPTARES THERAPEUTICS LTD [GB]) 16 April 2020 (2020-04-16) Abstract; table 1 on pp. 21-25; examples A-C; Claims	1-25
Y	----- JOHN S. DAVIES: "The cyclization of peptides and depsipeptides", JOURNAL OF PEPTIDE SCIENCE, vol. 9, no. 8, 1 January 2003 (2003-01-01) , pages 471-501, XP055214998, ISSN: 1075-2617, DOI: 10.1002/psc.491 Review of techniques for cyclization of peptides and depsipeptides. Lactam bridges. ----- -/-	1-25



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

12 November 2021

Date of mailing of the international search report

22/11/2021

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

López García, F

INTERNATIONAL SEARCH REPORT

International application No
PCT/GB2021/051921

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EUNICE N. MURAGE ET AL: "Development of Potent Glucagon-like Peptide-1 Agonists with High Enzyme Stability via Introduction of Multiple Lactam Bridges", JOURNAL OF MEDICINAL CHEMISTRY, vol. 53, no. 17, 9 September 2010 (2010-09-09), pages 6412-6420, XP055052407, ISSN: 0022-2623, DOI: 10.1021/jm100602m Lactam bridges for enzymatic stabilization of GLP-1 -----	1-25
Y	BIKASH MANANDHAR ET AL: "Glucagon-like Peptide-1 (GLP-1) Analogs: Recent Advances, New Possibilities, and Therapeutic Implications", JOURNAL OF MEDICINAL CHEMISTRY, vol. 58, no. 3, 12 February 2015 (2015-02-12), pages 1020-1037, XP055402142, US ISSN: 0022-2623, DOI: 10.1021/jm500810s Lactam bridges for helical stabilization in GLP-1 -----	1-25

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/GB2021/051921

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2020074927 A2	16-04-2020	AU 2019358324 A1	22-04-2021
		CA 3115448 A1	16-04-2020
		CN 113166206 A	23-07-2021
		EP 3863661 A2	18-08-2021
		WO 2020074927 A2	16-04-2020
